[1] 李晨越,陈思恬,何芮,等.RhD主动免疫安全性研究[J].中国输血杂志,2021,34(5):489-493. [2] 赵震,张冬霞,王晓宁,等.9684例输血患者Rh血型系统抗原频率及不规则抗体检测临床价值分析[J].中国实验诊断学,2020,24(1):139-141. [3] AVENT N D,REID M E.The Rh blood group system:a review[J].Blood,2000,95(2):375-387. [4] MIJOVIC A.Alloimmunization to RhD antigen in RhD-incompatible haemopoietic cell transplants with non-myeloablative conditioning[J].Vox Sang,2002,83(4):358-362. [5] YAZER M,TRIULZI D.Detection of anti-D in D-recipients transfused with D+ red blood cells[J].Transfusion,2007,47(12):2197-2201. [6] CID J,LOZANO M,KLEIN H G,et al.Matching for the D antigen in haematopoietic progenitor cell transplantation:definition and clinical outcomes[J].Blood Transfus,2014,12(3):301-306. [7] LUO X D,KELLER M A,JAMES I,et al.Strategies to identify candidates for D variant genotyping[J].Blood Transfus,2018,16(3):293-301. [8] BOGGIONE C T,LUJÁN BRAJOVICH M E,MATTALO NI S M,et al.Genotyping approach for non-invasive foetal RHD detection in an admixed population[J].Blood Transfus,2017,15(1):66-73. [9] CARRERAS E,DUFOUR C,MOHTY M,et al.The EBMT Handbook:Hematopoietic Stem Cell Transplantation and Cellular Therapies[M].Cham:Springer International Publishing,2019. [10] Stephen J.Forman等著.吴德沛,黄晓军主译.THOMAS造血干细胞移植[M].第5版.北京:中国科学技术出版社,2020:1169-1181. [11] 雷红,董梅,李振才,等.Rh(D)血型不合的异基因外周血干细胞移植1例报告[J].北京医学,2008,30(2):122-123. [12] WOREL N,BÖHM A,RABITSCH W,et al.Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning[J].Transfusion,2012,52(6):1348-1353. [13] TIWARI A K,ARORA D,AGGARWAL G,et al.Safety assessment of RhD-positive red cell transfusion in RhD-negative liver-transplant recipients:single-centre report from India[J].Indian J Med Res,2020,152(6):662-666. [14] CASANUEVA M,VALDES M D,RIBERA M C.Lack of alloimmunization to D antigen in D-negative immunosuppressed liver transplant recipients[J].Transfusion,1994,34(7):570-572. [15] CID J,LOZANO M,FERNÁNDEZ-AVILÉS F,et al.Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases[J].Transfusion,2006,46(2):169-173. [16] 国家质量监督检验检疫总局,中国国家标准化管理委员会.全血及成分血质量要求:GB 18469—2012[S].北京:中国标准出版社,2012. [17] LOZANO M,CID J.The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility[J].Transfus Med Rev,2003,17(1):57-68. [18] WEINSTEIN R,SIMARD A,FERSCHKE J,et al.Prospective surveillance of D- recipients of D+ apheresis platelets:alloimmunization against D is not detected[J].Transfusion,2015,55(6):1327-1330. [19] LIUMBRUNO G,BENNARDELLO F,LATTANZIO A,et al.Recommendations for the transfusion of plasma and platelets[J].Blood Transfus,2009,7(2):132-150. [20] 罗观文,梁栋立,洪好武,等.Rh阴性抗-D人免疫球蛋白的研究进展[J].华西药学杂志,2019,34(2):179-182. [21] QURESHI H,MASSEY E,KIRWAN D,et al.BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn[J].Transfus Med,2014,24(1):8-20. [22] DUNBAR N M.Does ABO and RhD matching matter for platelet transfusion?[J].Hematology Am Soc Hematol Educ Program,2020,2020(1):512-517. [23] POSTON J N,SUGALSKI J,GERNSHEIMER T B,et al.Mitigation strategies for anti-D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients:a survey of NCCN® centres[J].Vox Sang,2020,115(4):334-338. |